Clinical Trial Update: Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]

View source ↗

Summary

An extension study of two doses of Linsitinib for Thyroid Eye Disease is in Phase 2/3 and currently recruiting, sponsored by Sling Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy
• Hashimoto Thyroiditis
• Thyroid Eye Disease

Drugs mentioned

• Linsitinib (linsitinib)

Snippet

Sponsor: Sling Therapeutics, Inc. | Conditions: Thyroid Eye Disease, Graves Orbitopathy | Phase 2, Phase 3 | Status: RECRUITING